Study Shows Low Incidence of Early Toxicity Using Stereotactic Body Radiation Therapy (SBRT) While Eliminating Potential Complications and Costs Associated with Implanted Markers
Leveraging on-table MR soft tissue imaging, MRIdian allows oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that’s simply unavailable with conventional IGRT technologies.
Combining the latest innovations in precision radiation delivery, ground-breaking MR image guidance, and on-table adaptive therapy, MRIdian represents a new paradigm in radiation oncology.
Study Shows Low Incidence of Early Toxicity Using Stereotactic Body Radiation Therapy (SBRT) While Eliminating Potential Complications and Costs Associated with Implanted Markers
ViewRay® to Participate in Upcoming Investor Conferences
ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in two upcoming investor conferences in New York, NY - Sept. 4th and 11th, 2019.
ViewRay Reports Second Quarter 2019 Results
ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2019.
A new kind of medical technology company—ViewRay® Inc. designs, manufactures and markets MRIdian, the world’s first MRI-Guided radiation therapy system to image and treat cancer patients simultaneously.
Contact Us Today To Learn More Contact
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy